Document:

EX-10.1

 Exhibit 10.1 

GENERAL RELEASE 

GENERAL RELEASE (the “Release”), by William J. Enright (the “Executive”)
in favor of Altimmune, Inc. (the “Company”) and the Company Releasees (as hereinafter defined), dated as of November 30, 2018. 

Capitalized terms used herein but not specifically defined shall have the meanings set forth in the Employment Agreement between the Executive
and the Company, dated as of December 7, 2015, as amended by the First Amendment to the Employment Agreement, effective as of January 18, 2017 (together, the “Employment Agreement”). 

1. Termination. In connection with the Executive’s resignation of employment for Good Reason, effective on the date hereof (the
“Termination Date”), the Executive hereby confirms his resignation from all positions with the Company and its affiliates, including as an officer, director, employee, or fiduciary of the Company or any affiliate. The Executive will
execute such letters or documents that the Company or any affiliate deems necessary and proper to effect the foregoing resignations. 
 2.
Separation Benefits. In addition to the Accrued Obligations, in connection with the Executive’s resignation of employment, the Company has agreed to provide the Executive with—subject to the Executive’s timely execution,
delivery, and non-revocation of this Release, and subject further to the Executive’s continued compliance with the obligations described in Sections 11 and 12 of this Release—the following
payments and benefits, in each case, in full satisfaction of the Company’s obligations to the Executive upon the Executive’s termination of employment with the Company whether pursuant to the Employment Agreement or otherwise, and subject
to the terms and conditions set forth therein: 
 a. $448,000, as a cash severance payment, payable in equal monthly installments over the
twelve (12) month period following the Termination Date in accordance with the Company’s regular payroll practices, except that the first installment will be paid on the Company’s regular payroll on the fifteenth (15th) day
following the Termination Date and shall include payment of any amounts that would otherwise be due prior thereto; 
 b. subject to the
Executive’s timely election, and the availability, of COBRA continuation coverage, a monthly payment on the Executive’s behalf for COBRA continuation coverage for twelve (12) months following the Termination Date, equal to $22,424.26
in the aggregate, in satisfaction of the Company’s obligation under Section 6(b)(ii) of the Employment Agreement for COBRA Assistance, except that the first installment will be paid on the Executive’s behalf on the fifteenth
(15th) day following the Termination Date and shall include payment of any amounts that would otherwise be due prior thereto, and provided further, however, that if at any time the
Company determines that the COBRA Assistance would result in a violation of the non-discrimination rules under Code Section 105(h)(2) or any other applicable laws, statute, or regulation of similar effect (including, but not limited to, the
2010 Patient Protection and Affordable Care Act, as amended), then in lieu of providing the COBRA Assistance, the Company will instead pay the Executive fully taxable cash payments equal to, and paid at the same time as, the COBRA Assistance that
would have otherwise been paid. 

  
 1 

 c. $184,800, in respect of the Executive’s Annual Bonus for the year of termination, pro-rated based on the number of full calendar months through the Termination Date, based on actual performance through the Termination Date (which the Executive and the Company hereby agree results in achievement
at 90% of the Executive’s target award), payable on the Company’s regular payroll on the on the fifteenth (15th) day following the Termination Date. 

Without limiting the generality of anything contained in this Release, the Executive expressly agrees and acknowledges that all of the
Executive’s outstanding stock option awards shall be subject to the terms and conditions of the applicable plan document and stock option award agreements. 

3. No Other Compensation or Benefits. Executive’s participation in and rights under the Company’s 401(k) plans shall be
subject to the applicable terms of such plans. The Cash Severance Amount, Accrued Obligations, and other benefits set forth in Section 2 of this Release shall constitute the entire, maximum, and only obligation of the Company to Executive under
this Release or otherwise, and Executive is not entitled to any other benefit payment or compensation in any form, including without limitation the payment of any expense reimbursement, personal holidays, vacation or personal time off pay, bonuses,
or health, welfare, or retirement benefits or rights, from the Company or any Company Releasees (as that term is defined below). 
 4.
General Release. The Executive, for the Executive and for the Executive’s heirs, executors, administrators, successors, and assigns (referred to collectively as “Releasors”) hereby irrevocably and unconditionally, and
knowingly and voluntarily, waives, terminates, cancels, releases, and discharges forever the Company and its subsidiaries, affiliates, and related entities and any and all of their respective predecessors, successors, assigns, and employee benefit
plans, together with each of their respective owners, assigns, agents, general and limited partners, shareholders, directors, officers, employees, attorneys, advisors, trustees, fiduciaries, administrators, agents, and representatives, and any of
their predecessors and successors and each of their estates, successors, heirs and assigns (collectively, the “Company Releasees”) from any and all charges, allegations, complaints, claims, liabilities, obligations, promises,
agreements, causes of action, rights, costs, losses, debts, and expenses of any nature whatsoever, known or unknown, suspected or unsuspected (collectively, “Claims”) which the Executive or the Releasors ever had, now have, may
have, or hereafter can, will, or may have (either directly, indirectly, derivatively, or in any other representative capacity) by reason of any matter, fact, or cause whatsoever against the Company or any of the other Company Releasees:
(a) from the beginning of time to the date upon which the Executive signs this Release; (b) arising out of, or relating to, the Executive’s employment with the Company and/or the termination of the Executive’s employment; or
(c) arising out of or related to any agreement or arrangement between the Executive and/or any Company Releasees. This Release includes, without limitation, all claims for attorneys’ fees and punitive or consequential damages and all
claims arising under any federal, state, and/or local labor, employment, whistleblower, and/or anti-discrimination laws and/or regulations, including, without limitation, the Age Discrimination in Employment Act of 1967 (“ADEA”),
Title VII of the Civil Rights Act of 1964, the Employee Retirement Income Security 

  
 2 

 
Act of 1974, the Americans with Disabilities Act, the Family and Medical Leave Act, the Civil Rights Act of 1991, the Equal Pay Act, the Immigration and Reform Control Act, the Uniform Services
Employment and Re-Employment Act, the Rehabilitation Act of 1973, Executive Order 11246, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Worker Adjustment Retraining
and Notification Act, the Labor Management Relations Act, the National Labor Relations Act, Title 3 of Maryland’s Labor and Employment Code, the Maryland Wage Payment and Collection Act, the anti-discrimination ordinances of Montgomery County
(Montgomery Cty., Md., Code §§ 27-11, et seq.), and any similar federal, Maryland or other state, or municipal act, statute, or ordinance, including all amendments to any of the aforementioned
acts, statutes, or ordinances or under any common law or equitable theory including, but not limited to, tort, breach of contract, fraud, fraudulent inducement, promissory estoppel, and defamation and violations of any other federal, state, or
municipal fair employment acts, statutes, or laws, including, without limitation, violations of any other act, statute, law, rule, regulation, or ordinance pertaining to employment, wages, compensation, hours worked, or any other matters related in
any way to the foregoing; provided, however, that nothing in this Release shall release or impair any rights that cannot be waived under applicable law. 

5. Surviving Claims. Notwithstanding anything herein to the contrary, this Release shall not: 

a. limit or prohibit in any way the Executive’s (or the Executive’s beneficiaries’ or legal representatives’) rights to
bring an action to enforce the terms of this Release; 
 b. release any claim for employee benefits under plans covered by the Employee
Retirement Income Security Act of 1974, as amended, to the extent that such claims may not lawfully be waived, or for any payments or benefits under any benefit plans of the Company and its affiliates in which the Executive was a participant as of
the Termination Date that have accrued or vested in accordance with and pursuant to the terms of those plans; 
 c. waive or release any
rights or claims Executive may have to workers’ compensation or unemployment benefits; or 
 d. waive or release any other claims or
rights which cannot be waived by law. 
 6. Executive Representations. The Executive represents and warrants that no Releasor has
filed any civil action, suit, arbitration, administrative charge, complaint, lawsuit, or legal proceeding against any Company Releasee nor has any Releasor assigned, pledged, or hypothecated, as of the date hereof, Executive’s claim to any
person and no other person has an interest in the Claims that Executive is releasing. Executive further represents and warrants that Executive has no known workplace injuries or occupational diseases. 

7. Pursuit of Released Claims. Executive agrees and covenants not to file any suit, action, arbitration, or complaint against any
of the Company Releasees for claims released in this Release and, except as provided for in Section 10 of this Release, not to assist in any such action in any court or private proceeding with regard to any claim, demand, liability, or
obligation arising out of his employment with the Company or separation therefrom. Nothing in this Release shall interfere with Executive’s right to respond accurately and fully to any question, inquiry, or request for information when required
by legal process (e.g., a valid subpoena or other similar compulsion of law). 

  
 3 

 8. Nonadmission of Liability. Executive acknowledges that neither this Release
and the consideration offered in it, nor the Company’s performance hereunder, constitutes an admission by the Company or any of the Company Releasees of any violation of any federal, state, or local law, ordinance, regulation, public policy, or
any common law rule, breach of any contract, commission of any wrongdoing, or liability whatsoever. 
 9. Acknowledgements by
Executive. The Executive acknowledges and agrees that Executive has read this Release in its entirety and that this Release is a general release of all known and unknown rights and Claims, including, without limitation, of rights and Claims
arising under ADEA. The Executive further acknowledges and agrees that: 
 a. this Release does not release, waive, or discharge any rights
or claims that may arise for actions or omissions after the date the Executive executes this Release; 
 b. the Executive is entering into
this Release and releasing, waiving, and discharging rights or claims only in exchange for consideration that the Executive is not already entitled to receive; 

c. the Executive has been advised, and is being advised by this Release, to consult with an attorney before executing this Release, and the
Executive has consulted (or had an opportunity to consult) with counsel of the Executive’s choice concerning the terms and conditions of this Release; 

d. the Executive has been advised, and is being advised by this Release, that the Executive has
twenty-one (21) days within which to consider this Release, and the Executive hereby acknowledges that in the event that the Executive executes this Release before the expiration of the 21-day period, the Executive waives the balance of said period and acknowledges that the Executive’s waiver of such period is knowing, voluntary, and has not been induced by the Company or any Company Releasee
through fraud, misrepresentation, or threat; and 
 e. the Executive is aware that this Release shall become void if the Executive revokes
the Executive’s agreement to this Release within seven (7) days following the date of execution of this Release. The Executive may revoke this Release at any time during such seven-day period by
delivering (or causing to be delivered) to the Chief Executive Officer of the Company at 910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878 written notice of the Executive’s revocation of this Release no later than the seventh (7th)
full day following the date of execution of this Release. 
 10. Additional Agreements. Nothing in this Release shall prohibit the
Executive from filing a charge with, providing information to, or cooperating with any governmental agency and in connection therewith obtaining a reward or bounty, but the Executive agrees that should any person or entity file or cause to be filed
any civil action, suit, arbitration, or other legal proceeding seeking equitable or monetary relief concerning any claim released by the Executive herein, 

  
 4 

 
neither the Executive nor any Releasor shall seek or accept any such damages or relief from or as the result of such civil action, suit, arbitration, or other legal proceeding filed by the
Executive or any action or proceeding brought by another person, entity, or governmental agency. In addition, nothing in this Release (including, without limitation, Section 12 below) shall be construed to prohibit the Executive from
(a) reporting or disclosing information under the terms of the Company’s policy concerning reporting suspected violations of law or (b) reporting possible violations of federal law or regulations, including any possible securities
laws violations, to any governmental agency or entity, including the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; making any other disclosures that are protected under
the whistleblower provisions of federal law or regulations; otherwise fully participating in any federal whistleblower programs, including any such programs managed by the U.S. Securities and Exchange Commission; or receiving individual monetary
awards or other individual relief by virtue of participating in any such federal whistleblower programs (it being understood that prior authorization of the Company is not required to make any such reports or disclosures, and the Executive is not
required to notify the Company that he has made such reports or disclosures). 
 11. Restrictive Covenants, Assistance in Litigation, Tax
Withholding, and Code § 409A Compliance. The Executive expressly acknowledges and agrees that his obligations under Section 7 (Secrecy, Non-Solicitation and Non-Competition) and Section 12 (Assistance in Litigation) of the Employment Agreement shall remain in full force and effect after the date hereof, notwithstanding anything to the contrary in this Release. In
addition, for the avoidance of doubt, Sections 20 and 21 of the Employment Agreement concerning compliance with tax withholding and Code Section 409A shall apply to all payments referred to in this Release. 

12. No Disparagement. Subject to Section 10, the Executive agrees to refrain from any publication and any type of communication,
whether oral or written, of a defamatory or disparaging nature concerning the Company, its affiliates, or its past, present, and future officers, directors, agents, employees, or representatives. The Company agrees to instruct its directors and
executive officers to refrain from any publication and any type of communication, whether oral or written, of a defamatory or disparaging nature concerning the Executive. 

13. Waiver. The failure of either of the parties hereto to at any time enforce any of the provisions of this Release shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Release or any term hereof or the right of either of the parties hereto thereafter to enforce each and every term of this Release. No waiver of any
breach of any of the terms of this Release shall be effective unless set forth in a written instrument executed by the party against whom or which enforcement of such waiver is sought, and no waiver of any such breach shall be construed or deemed to
be a waiver of any other or subsequent breach. 
 14. Company Property. Executive represents and warrants that he has turned over to
the Company all property of the Company, including without limitation all files, memoranda, keys, manuals, equipment, data, records, and other documents, including electronically recorded documents and data that Executive received from the Company
or its employees or that Executive generated in the course of his employment with the Company. Executive further represents he no longer retains, in paper or electronic format, any data, property, or documents that Executive

  
 5 

 
received from the Company or its employees or that Executive generated in the course of his employment with the Company. Executive represents and certifies that he has permanently deleted any and
all electronic data of the Company from all of Executive’s computers and electronic communications and storage devices, as well as Executive’s electronic accounts, including but not limited to email and cloud-based computing accounts. 

15. Governing Law. This Release is made and entered into in the State of Maryland, and the laws of the State of Maryland shall govern
its validity and interpretation, without regard to conflict of laws rules. 
 16. Consent to Venue, Service, and Personal
Jurisdiction. Any dispute, controversy, or claim arising out of this Release or the breach thereof shall be brought in the state or federal courts located in the State of Maryland. The Executive irrevocably (a) accepts generally and
unconditionally the exclusive jurisdiction and venue of state and federal courts located in the State of Maryland; (b) waives any defense of forum non conveniens; (c) agrees that service of all process in any such proceeding in any
such court may be made by registered or certified mail, return receipt requested, to the applicable party at its address provided in Section 13 of the Employment Agreement; and (d) agrees that service as provided in clause (c) above
is sufficient to confer personal jurisdiction over the Executive in any such proceeding in any such court, and otherwise constitutes effective and binding service in every respect. 

17. WAIVER OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY DISPUTE,
CONTROVERSY, OR CLAIM, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, AMONG THE PARTIES HERETO ARISING OUT OF OR RELATING IN ANY WAY TO THE EMPLOYMENT OF THE EXECUTIVE OR TERMINATION THEREOF OR FOR ANY COUNTERCLAIM THEREIN. THE PARTIES HERETO MAY
FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS RELEASE WITH ANY COURT OF COMPETENT JURISDICTION AS PROVIDED HEREIN AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. 

18. Amendment. No provision of this Release may be modified, changed, waived, or discharged unless such waiver, modification, change, or
discharge is agreed to in writing and signed by the Company and the Executive. 
 19. Entire Agreement. When read in conjunction with
the surviving portions of the Employment Agreement referenced herein, this Release constitutes the entire agreement with the parties relating to the Executive’s separation from and release of claims against the Company and the Company
Releasees. 
 20. Severability and Reformation. If a court finds any term of this Release invalid or unenforceable as applied to any
circumstance, the remainder of this Release and the application of such term shall be interpreted so as to best effect the intent of the parties hereto. The parties further agree and consent to the court replacing or revising any such void or
unenforceable term in this Release such that it is a valid and enforceable term that will achieve, to the extent possible, the economic, business, or other purposes of the void or unenforceable term. 

  
 6 

 21. Counterparts. This Release may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which shall together constitute one in the same Release. 
 Signature page follows. 

  
 7 

 IN WITNESS WHEREOF, the Company and the Executive have signed this Release on the dates set
forth below. 
  

			
	EXECUTIVE
		
	By:	 	 /s/ William J. Enright

	Name:	 	William J. Enright
		
	Date:	 	November 30, 2018
	
	ALTIMMUNE, INC.
		
	By:	 	 /s/ William Brown

	Name:	 	William Brown
	Title:	 	Acting Chief Financial Officer
		
	Date:	 	November 30, 2018

  
 8EX-10.2

 Exhibit 10.2 
  

 
 ALTIMMUNE, INC. 

CONSULTING AGREEMENT 
 This
Consulting Agreement (the “Agreement”) is hereby made and entered into as of the 30th day of November, 2018 (the “Effective Date”), by and between Altimmune, Inc., a Delaware corporation (“Altimmune” or
“Company”), having a place of business at 910 Clopper Road, Gaithersburg, Maryland 20878 and William Enright, an individual, residing at and conducting business at 12312 Chagall Dr., N. Potomac, MD 20878 (“Consultant”). 

1. Engagement of Services. During the period of this Agreement, Consultant hereby agrees to provide consulting services to Altimmune on
an as needed basis to provide review and analysis in areas of their expertise to support business discussions, venture capital discussions, grants, contracts and other areas as mutually agreed. Consultant recognizes that Altimmune is engaged in a
continuous program of research, development, production, and commercialization of non-invasive vaccines and other therapies, and that, as part of Consultant’s assistance to Altimmune pursuant to this
Agreement, Consultant may, and indeed Altimmune hopes will, make innovative contributions and inventions of value to Altimmune. 
 2.
Compensation; Timing. In consideration for the consulting services bargained for in this Agreement, Altimmune will compensate the Consultant with the following: 

a. Consulting Fee. An hourly consulting fee of two hundred thirty-three Dollars per hour ($233/hour), for each hour of service provided.
Subject to the terms in Sections 6.2 and 6.3, Altimmune agrees to pay Consultant in eighty-hour increments on December 3, 2018, January 2, 2019 and February 1, 2019. Thereafter, for any time in excess of such two hundred forty
(240) hours, Consultant shall invoice the Company for Services rendered and such invoice will be paid upon thirty (30) days of receipt. Consulting fee shall not exceed fifty-five thousand nine hundred twenty Dollars ($55,920) during the
Term (as defined below) without prior written approval. 
 b. Expense Reimbursement. Altimmune will reimburse your reasonable travel
and other out-of-pocket expenses incurred by you from time to time at Altimmune’s request. Any expenses in excess of
one-hundred dollars ($100) must be pre-approved by Altimmune. Pre-approval of expenses related to the Board meeting in Charlotte,
North Carolina and JPMorgan activities in San Francisco, California have been obtained. Consultant will be reimbursed for such expenses no later than thirty (30) days after Altimmune’s receipt of Consultant’s invoice, provided that
reimbursement for expenses may be delayed until such time as Consultant has furnished such documentation for authorized expenses as Altimmune may reasonably request. 

3. Independent Contractor Relationship. Consultant’s relationship with Altimmune is that of an independent contractor, and nothing
in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. Consultant will not be entitled to any of the benefits which Altimmune may make available to its employees,

 

 
  

 
including, but not limited to, group health or life insurance, profit-sharing or retirement benefits. Consultant is not authorized to make any representation, contract or commitment on behalf of
Altimmune unless specifically requested or authorized in writing to do so by Altimmune’s President & CEO. Consultant is solely responsible for, and will file, on a timely basis, all tax returns and payments required to be filed with,
or made to, any federal, state or local tax authority with respect to the performance of services and receipt of fees under this Agreement. Consultant is solely responsible for, and must maintain adequate records of, expenses incurred in the course
of performing services under this Agreement. No part of Consultant’s compensation will be subject to withholding by Altimmune for the payment of any social security, federal, state or any other employee payroll taxes. Altimmune will regularly
report amounts paid to Consultant by filing Form 1099-MISC with the Internal Revenue Service as required by law. 
 4. Intellectual
Property Rights. 
 4.1 Disclosure and Assignment of Innovations: 

(a) Innovations; Altimmune Innovations. “Innovations” includes processes, machines, compositions of matter, improvements,
inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), moral rights, mask works, trademarks, trade names, trade dress,
trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and all other subject matter protectable under patent, copyright, moral right, mask work, trademark, trade secret or other
laws, and includes, without limitation, all new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software, and designs. “Altimmune Innovations” are Innovations that
Consultant, solely or jointly with others, conceives, reduces to practice, creates, derives, develops or makes within the scope of Consultant’s work for Altimmune under this Agreement. 

(b) Disclosure of Ownership of Altimmune Innovations. Consultant agrees to make and maintain adequate and current records of all
Altimmune Innovations, which records shall be and remain the property of Altimmune. Consultant agrees to promptly disclose to Altimmune every Altimmune Innovation. Consultant hereby does and will assign to Altimmune or Altimmune’s designee,
Consultant’s entire worldwide right, title and interest in and to all Altimmune Innovations and all associated records and intellectual property rights. 

(c) Assistance. Consultant agrees to execute, upon Altimmune’s request, a signed transfer of Altimmune Innovations to Altimmune in
the form attached as EXHIBIT A for each of Altimmune’s Innovations, including, but not limited to, computer programs, notes, sketches, drawings and reports. Consultant agrees to assist Altimmune in any

  
 2 

 

 
  

 
reasonable manner to obtain, perfect and enforce, for Altimmune’s benefit, Altimmune’s rights, title and interest in any and all countries, in and to all patents, copyrights, moral
rights, mask works, trade secrets, and other property rights in each of Altimmune’s Innovations. Consultant agrees to execute, when requested, for each of Altimmune’s Innovations (including derivative works, improvements, renewals,
extensions, continuations, divisionals, continuations in part, or continuing patent applications thereof), (i) patent, copyright, mask work or similar applications related to such Altimmune Innovation, (ii) documentation (including, without
limitation, assignments) to permit Altimmune to obtain, perfect and enforce Altimmune’s right, title and interest in and to such Altimmune Innovation, and (iii) any other lawful documents deemed necessary by Altimmune to carry out the
purpose of this Agreement. If called upon to render assistance under this paragraph, Consultant will be entitled to a fair and reasonable fee in addition to reimbursement of authorized expenses incurred at the prior written request of Altimmune. In
the event that Altimmune is unable for any reason to secure Consultant’s signature to any document is required to execute under this Paragraph 4.1(c), Consultant hereby irrevocably designates and appoints Altimmune and Altimmune’s duly
authorized officers and agents as Consultant’s agents and attorneys-in-fact to act for and in Consultant’s behalf and instead of Consultant, to execute such
document with the same legal force and effect as if executed by Consultant. 
 4.2 Confidential Information. 

(a) Definition of Confidential Information. “Confidential Information” as used in this Agreement shall mean any and all
technical and non-technical information including patent, copyright, trade secret, and proprietary information, techniques, sketches, drawings, models, inventions,
know-how, processes, apparatus, equipment, algorithms, software programs, software source documents, and formulae related to the current, future and proposed product and services of Altimmune, Altimmune’s
suppliers and customers, and includes, without limitation, Altimmune Innovations, Altimmune Property, and Altimmune’s information concerning research, experimental work, development, design details and specifications, engineering, financial
information, procurement requirements, purchasing manufacturing, customer lists, business forecasts, sales and merchandising and marketing plans and information. 

(b) Nondisclosure and Nonuse Obligations. Except as permitted in this paragraph, Consultant shall neither use nor disclose the
Confidential Information. Consultant may use the Confidential Information solely to perform the consulting services bargained in this Agreement for the benefit of Altimmune. Consultant agrees that Consultant shall treat all Confidential Information
of Altimmune with the same degree of care as Consultant accords to Consultant’s own Confidential Information, but in no case less than reasonable care. Consultant agrees not to communicate any information to Altimmune in violation of the
proprietary rights of any third party. Consultant will immediately give notice to Altimmune of any unauthorized use or disclosure of the Confidential Information. Consultant agrees to assist Altimmune in remedying any such unauthorized use or
disclosure of the Confidential Information. 

  
 3 

 

 
  

 (c) Exclusion from Nondisclosure and Nonuse Obligations. Consultant’s
obligations under Paragraph 4.2(b) (“Nondisclosure and Nonuse Obligations”) with respect to any portion of the Confidential Information shall not apply to any such portion which Consultant can demonstrate: (a) was in the public domain
at or subsequent to the time such portion was communicated to Consultant by Altimmune through no fault of Consultant; (b) was rightfully in Consultant’s possession free of any obligation of confidence at or subsequent to the time such
portion was communicated to Consultant by Altimmune; or (c) was developed by Consultant independently of and without reference to any information communicated to Consultant by Altimmune. A disclosure of Confidential Information by Consultant,
either (a) in response to a valid order by a court or other governmental body, (b) otherwise required by law, or (c) necessary to establish the rights of either party under this Agreement, shall not be considered to be a breach of
this Agreement or a waiver of confidentiality for other purposes; provided, however, that Consultant shall provide prompt prior written notice thereof to Altimmune to enable Altimmune to seek a protective order or otherwise prevent such disclosure.

 4.3 Ownership and Return of Altimmune Property. All materials (including, without limitation, documents, drawings, models,
apparatus, sketches, designs, lists, and all other tangible media of expression) furnished to Consultant by Altimmune, whether delivered to Consultant by Altimmune or made by Consultant in the course of performing the consulting services bargained
for in this Agreement (collectively, the “Altimmune Property”) are the sole and exclusive property of Altimmune or Altimmune’s suppliers or customers, and Consultant hereby does and will assign to Altimmune all rights, title and
interest Consultant may have or acquire in Altimmune’s Property. Consultant agrees to keep all Altimmune Property at Consultant’s premises unless otherwise permitted in writing by Altimmune. At Altimmune’s request, and no later than
five (5) days after such request, Consultant shall destroy or deliver to Altimmune, at Altimmune’s option, (a) all Altimmune Property, (b) all tangible media of expression in Consultant’s possession or control which
incorporate or in which are fixed any Confidential Information, and (c) written certification of Consultant’s compliance with Consultant’s obligations under this sentence. 

4.4 Observance of Altimmune Rules. At all times while on Altimmune’s premises, Consultant will observe Altimmune’s rules and
regulations with respect to conduct, health and safety and protection of persons and property. 
 5. No Conflict of Interest. During
the term of this Agreement, Consultant will not accept work, enter into a contract, or accept an obligation, inconsistent or incompatible with Consultant’s obligations, or the scope of service rendered for Altimmune, under this Agreement.
Consultant warrants that, to the best of Consultant’s knowledge, there is no other contract or duty on Consultant’s part which conflicts with or is inconsistent with this Agreement. 

  
 4 

 

 
  

 6. Term and Termination. 

6.1 Term. This Agreement is effective as of the Effective Date set forth above and will terminate on February 28, 2019. The
Agreement may be extended by mutual agreement in writing. 
 6.2 Termination by Altimmune. Altimmune may terminate this Agreement
without cause at any time, with termination effective fifteen (15) days after Altimmune’s delivery to Consultant of written notice of termination. Altimmune also may terminate this Agreement (i) immediately upon Consultant’s
breach of Paragraph 4 (“Intellectual Property Rights”) or 7 (“Noninterference with Business”), or (ii) thirty (30) days after Altimmune’s delivery to Consultant of written notice of Consultant’s material breach of
any other provision or obligation owed by Consultant under this Agreement which is not cured within such thirty (30) day period. In the event of termination of this agreement, the Consultant will refund Altimmune for the excess of the hours
paid (Section 2.a.) less the actual hours incurred by Consultant multiplied by the hourly rate of $233. 
 6.3 Termination by
Consultant. Consultant may terminate this Agreement without cause at any time, with termination effective fifteen (15) days after Consultant’s delivery to Altimmune of written notice of termination. Consultant also may terminate this
Agreement for material breach by Altimmune if Altimmune has not cured the breach within thirty (30) days of receiving written notice from Consultant. In the event of termination by the Consultant, the Consultant will refund Altimmune for the
excess of the hours paid (Section 2.a.) less the actual hours incurred by Consultant multiplied by the hourly rate of $233. 
 6.4
Survival. The definitions contained in this Agreement and the rights and obligations contained in Paragraphs 4 (“Intellectual Property”), 6.4 (“Survival”), 7 (“Noninterference with Business”), and 8
(“General Provisions”) will survive any termination or expiration of this Agreement. 
 7. Noninterference with Business.
During this Agreement, and for a period of one (1) year immediately following this Agreement’s termination or expiration, Consultant agrees not to interfere with the business of Altimmune in any manner. By way of example and not of
limitation, Consultant agrees not to solicit or induce any employee or independent contractor to terminate or breach an employment, contractual or other relationship with Altimmune. 

  
 5 

 

 
  

 8. General Provisions. 

8.1 Successors and Assigns. Consultant may not subcontract or otherwise delegate Consultant’s obligations under this Agreement
without Altimmune’s prior written consent. Subject to the foregoing, this Agreement will be for the benefit of Altimmune’s successors and assigns, and will be binding on Consultant’s assignees. 

8.2 Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows, with notice
deemed given as indicated: (a) by personal delivery, when delivered personally; (b) by overnight courier, upon written verification of receipt; (c) by telecopy or facsimile transmission, upon acknowledgment of receipt of electronic
transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth above or to such other address as either party may specify in writing. 

8.3 Governing Law. This Agreement shall be governed in all respects by the laws of the United States of America and by the laws of the
State of Maryland. 
 8.4 Severability. If any provision of this Agreement is held by a court of law to be illegal, invalid or
unenforceable, (i) that provision shall be deemed amended to achieve as nearly as possible the same economic effect as the original provisions, and (ii) the legality, validity and enforceability of the remaining provisions of this
Agreement shall not be affected or impaired thereby. 
 8.5 Waiver; Amendment; Modification. No term or provision hereof will be
considered waived by Altimmune, and no breach excused by Altimmune, unless such waiver or consent is in writing signed by Altimmune. The waiver by Altimmune of, or consent by Altimmune to, a breach of any provision of this Agreement by Consultant
shall not operate or be construed as a waiver of, consent to, or excuse of any other or subsequent breach by Consultant. This Agreement may be amended or modified only by mutual agreement of authorized representatives of the parties in writing. 

8.6 Injunctive Relief for Breach. Consultant’s obligations under this Agreement are of a unique character that gives them
particular value; Consultant’s breach of any of such obligations will result in irreparable and continuing damage to Altimmune for which there will be no adequate remedy at law; and, in the event of such breach, Altimmune will be entitled to
injunctive relief and/or a decree for specific performance, and such other or further relief as may be proper (including monetary damages if appropriate). 

  
 6 

 

 
  

 8.7 Entire Agreement. This Agreement constitutes the entire agreement between the
parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all services undertaken by Consultant for Altimmune. 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 

 

					
	ALTIMMUNE, INC.	 		 	CONSULTANT
			
	By: /s/ Vipin Garg                                	 		 	/s/ William Enright                                
	Vipin Garg, President & CEO	 		 	William Enright

  
 7 

 

 
  

 EXHIBIT A 

ASSIGNMENT OF ALTIMMUNE INNOVATIONS 

For good and valuable consideration which has been received, the undersigned sells, assigns and transfers to ALTIMMUNE, INC.
(“Altimmune”), and Altimmune’s successors and assigns, and Altimmune accepts such sale, assignment and transfer of all rights, title and interest of CONSULTANT, vested and contingent, in and to Altimmune’s Innovations, and
all associated intellectual property rights (including, without limitation, patent, copyright, moral right, mask-work, and trade secret rights), which were conceived, reduced to practice, created, derived, developed or made during the course of the
services performed under the Consulting Agreement between Altimmune and Consultant dated as of                    201    . Such
Altimmune Innovations are more particularly identified in Schedule 1 hereto. 
 Executed as
of                    201    . 
  

									
	ALTIMMUNE, INC.	 		 	Consultant
					
	By:	 	 	 		 	By:	 	 
		 	Vipin Garg	 		 		 	William Enright
		 	President & CEO	 		 		 	

  
 8 

 

 
  

 SCHEDULE 1 

ASSIGNMENT OF ALTIMMUNE INNOVATIONS 

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]